Results 271 to 277 of about 101,286 (277)

Ipilimumab/nivolumab/Nivolumab/Nivolumab/relatlimab

Reactions Weekly
openaire   +1 more source

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

Nature Reviews Clinical Oncology
openaire   +2 more sources

Nivolumab

Reactions Weekly, 2019
  +4 more sources

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Cancer Cell, 2018
Matthew D Hellmann, Margaret K Callahan, Emiliano Calvo   +2 more
exaly  

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2017
Yoon-Koo Kang, Narikazu Boku, Taroh Satoh   +2 more
exaly  

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Lancet Oncology, The, 2017
Michael J Overman, Ray S Mcdermott, Sara Lonardi   +2 more
exaly  

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

Journal of Clinical Oncology, 2017
Jeffrey S Weber, F Stephen Hodi, Jedd D Wolchok   +2 more
exaly